TD Private Client Wealth LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 58.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,808 shares of the company's stock after buying an additional 6,201 shares during the period. TD Private Client Wealth LLC's holdings in AstraZeneca were worth $1,101,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Nordea Investment Management AB acquired a new position in shares of AstraZeneca in the fourth quarter worth about $754,000. Diversify Wealth Management LLC boosted its position in AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock valued at $295,000 after purchasing an additional 153 shares during the period. Ameritas Advisory Services LLC lifted its position in AstraZeneca by 25.9% in the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company's stock valued at $622,000 after purchasing an additional 1,949 shares during the last quarter. Oak Ridge Investments LLC boosted its position in shares of AstraZeneca by 5.4% during the fourth quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company's stock worth $9,433,000 after buying an additional 7,341 shares during the period. Finally, Asio Capital LLC grew its stake in shares of AstraZeneca by 11.6% in the fourth quarter. Asio Capital LLC now owns 53,541 shares of the company's stock worth $3,508,000 after purchasing an additional 5,569 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
AZN has been the topic of a number of research reports. Morgan Stanley assumed coverage on AstraZeneca in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock. UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $89.75.
View Our Latest Research Report on AstraZeneca
AstraZeneca Stock Up 0.2 %
AZN stock traded up $0.12 during midday trading on Thursday, hitting $72.84. The company's stock had a trading volume of 4,563,181 shares, compared to its average volume of 4,954,411. The stock has a market capitalization of $225.89 billion, a P/E ratio of 32.23, a PEG ratio of 1.42 and a beta of 0.41. AstraZeneca PLC has a twelve month low of $62.75 and a twelve month high of $87.68. The company's fifty day moving average price is $73.29 and its 200 day moving average price is $71.78. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.
AstraZeneca Increases Dividend
The firm also recently declared a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were issued a dividend of $1.03 per share. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. This represents a yield of 2%. The ex-dividend date was Friday, February 21st. AstraZeneca's dividend payout ratio (DPR) is presently 91.15%.
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
